Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade
Open Access
- 1 December 2004
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 88 (12) , 1543-1546
- https://doi.org/10.1136/bjo.2004.048587
Abstract
Background: Proliferative diabetic retinopathy (PDR) may be a response to abnormal angiogenic growth factors such as vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), and the soluble angiopoietin receptor tie-2. The authors hypothesised the following: (a) there are differences in plasma levels of these growth factors in different grades of diabetic retinopathy; and (b) that the effects of intervention with panretinal laser photocoagulation (PRP) for PDR, and angiotensin receptor blockade (using eprosartan) for patients with other grades of diabetic retinopathy will be to reduce levels of the growth factors. Methods: Cross sectional and interventional study (using PRP and eprosartan) in diabetic patients. VEGF, Ang-2, and tie-2 were measured by ELISA. Results: VEGF (pConclusion: Increased plasma levels of VEGF and Ang-2, as well as lower soluble tie-2, were found in diabetic patients. The highest VEGF and Ang-2 levels were seen among patients with pre-proliferative and proliferative retinopathy, but there was no relation of tie-2 to the severity of retinopathy. As the majority of previous research into Ang-2 and tie-2 has been in relation to angiogenesis and malignancy, the present study would suggest that Ang-2 and tie-2 may be used as potential indices of angiogenesis in diabetes mellitus (in addition to VEGF) and may help elucidate the role of the angiopoietin/tie-2 system in this condition.Keywords
This publication has 16 references indexed in Scilit:
- Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectivesDiabetes/Metabolism Research and Reviews, 2003
- The enigmatic role of angiopoietin-1 in tumor angiogenesisCell Research, 2003
- Plasma angiopoietin‐1, angiopoietin‐2 and Tie‐2 in breast and prostate cancer: a comparison with VEGF and Flt‐1European Journal of Clinical Investigation, 2003
- Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassayEuropean Journal of Clinical Investigation, 2003
- Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.2003
- Potential Role of the Angiopoietin/Tie2 System in Ischemia-Induced Retinal NeovascularizationInvestigative Opthalmology & Visual Science, 2003
- Vascular endothelial growth factors and angiogenesis in eye diseaseProgress in Retinal and Eye Research, 2003
- Vascular endothelial growth factor gene regulation and action in diabetic retinopathy.Ophthalmology Clinics of North America, 2002
- Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.2000
- New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGFOncogene, 1999